10x Genomics, Inc. (TXG)

Market Cap	3.92B
Revenue (ttm)	618.73M
Net Income (ttm)	-255.10M
Shares Out	119.17M
EPS (ttm)	-2.18
PE Ratio	n/a
Forward PE	196.08
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,238,640
Open	34.67
Previous Close	34.55
Day's Range	32.68 - 34.79
52-Week Range	32.68 - 63.57
Beta	1.89
Analysts	Buy
Price Target	59.30 (+80.46%)
Earnings Date	Apr 30, 2024

About TXG

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; si...

• Industry: Health Information Services
• Sector: Healthcare
• IPO Date: Sep 12, 2019
• Employees: 1,259
• Stock Exchange: NASDAQ
• Ticker Symbol: TXG

Financial Performance

In 2023, 10x Genomics's revenue was $618.73 million, an increase of 19.81% compared to the previous year's $516.41 million. Losses were -$255.10 million, 53.7% more than in 2022.

Analyst Forecast

According to 11 analysts, the average rating for TXG stock is "Buy." The 12-month stock price forecast is $59.3, which is an increase of 80.46% from the latest price.

Price Target

$59.3

(80.46% upside)

Analyst Consensus: Buy